img

Global PEGylated Drugs Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global PEGylated Drugs Market Insights, Forecast to 2034

Market Analysis and InsightsGlobal PEGylated Drugs Market
Global PEGylated Drugs market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022. Backed with the increasing demand from downstream industries, PEGylated Drugs industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global PEGylated Drugs market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global PEGylated Drugs market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Segment by Type
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles

Segment by Application


Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, PEGylated Drugs introduction, etc. PEGylated Drugs Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of PEGylated Drugs
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PEGylated Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Macromolecular Drugs
1.2.3 Small Molecular Drugs
1.2.4 Nanoparticles
1.3 Market by Application
1.3.1 Global PEGylated Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Hepatitis C
1.3.4 Leukemia
1.3.5 Severe Combined Immunodeficiency Disease
1.3.6 Rheumatoid Arthritis
1.3.7 Crohn Disease
1.3.8 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global PEGylated Drugs Market Perspective (2018-2029)
2.2 Global PEGylated Drugs Growth Trends by Region
2.2.1 PEGylated Drugs Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 PEGylated Drugs Historic Market Size by Region (2018-2024)
2.2.3 PEGylated Drugs Forecasted Market Size by Region (2024-2029)
2.3 PEGylated Drugs Market Dynamics
2.3.1 PEGylated Drugs Industry Trends
2.3.2 PEGylated Drugs Market Drivers
2.3.3 PEGylated Drugs Market Challenges
2.3.4 PEGylated Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue PEGylated Drugs by Players
3.1.1 Global PEGylated Drugs Revenue by Players (2018-2024)
3.1.2 Global PEGylated Drugs Revenue Market Share by Players (2018-2024)
3.2 Global PEGylated Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of PEGylated Drugs, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global PEGylated Drugs Market Concentration Ratio
3.4.1 Global PEGylated Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PEGylated Drugs Revenue in 2022
3.5 Global Key Players of PEGylated Drugs Head office and Area Served
3.6 Global Key Players of PEGylated Drugs, Product and Application
3.7 Global Key Players of PEGylated Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 PEGylated Drugs Breakdown Data by Type
4.1 Global PEGylated Drugs Historic Market Size by Type (2018-2024)
4.2 Global PEGylated Drugs Forecasted Market Size by Type (2024-2029)
5 PEGylated Drugs Breakdown Data by Application
5.1 Global PEGylated Drugs Historic Market Size by Application (2018-2024)
5.2 Global PEGylated Drugs Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America PEGylated Drugs Market Size (2018-2029)
6.2 North America PEGylated Drugs Market Size by Type
6.2.1 North America PEGylated Drugs Market Size by Type (2018-2024)
6.2.2 North America PEGylated Drugs Market Size by Type (2024-2029)
6.2.3 North America PEGylated Drugs Market Share by Type (2018-2029)
6.3 North America PEGylated Drugs Market Size by Application
6.3.1 North America PEGylated Drugs Market Size by Application (2018-2024)
6.3.2 North America PEGylated Drugs Market Size by Application (2024-2029)
6.3.3 North America PEGylated Drugs Market Share by Application (2018-2029)
6.4 North America PEGylated Drugs Market Size by Country
6.4.1 North America PEGylated Drugs Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America PEGylated Drugs Market Size by Country (2018-2024)
6.4.3 North America PEGylated Drugs Market Size by Country (2024-2029)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe PEGylated Drugs Market Size (2018-2029)
7.2 Europe PEGylated Drugs Market Size by Type
7.2.1 Europe PEGylated Drugs Market Size by Type (2018-2024)
7.2.2 Europe PEGylated Drugs Market Size by Type (2024-2029)
7.2.3 Europe PEGylated Drugs Market Share by Type (2018-2029)
7.3 Europe PEGylated Drugs Market Size by Application
7.3.1 Europe PEGylated Drugs Market Size by Application (2018-2024)
7.3.2 Europe PEGylated Drugs Market Size by Application (2024-2029)
7.3.3 Europe PEGylated Drugs Market Share by Application (2018-2029)
7.4 Europe PEGylated Drugs Market Size by Country
7.4.1 Europe PEGylated Drugs Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe PEGylated Drugs Market Size by Country (2018-2024)
7.4.3 Europe PEGylated Drugs Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China PEGylated Drugs Market Size (2018-2029)
8.2 China PEGylated Drugs Market Size by Type
8.2.1 China PEGylated Drugs Market Size by Type (2018-2024)
8.2.2 China PEGylated Drugs Market Size by Type (2024-2029)
8.2.3 China PEGylated Drugs Market Share by Type (2018-2029)
8.3 China PEGylated Drugs Market Size by Application
8.3.1 China PEGylated Drugs Market Size by Application (2018-2024)
8.3.2 China PEGylated Drugs Market Size by Application (2024-2029)
8.3.3 China PEGylated Drugs Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia PEGylated Drugs Market Size (2018-2029)
9.2 Asia PEGylated Drugs Market Size by Type
9.2.1 Asia PEGylated Drugs Market Size by Type (2018-2024)
9.2.2 Asia PEGylated Drugs Market Size by Type (2024-2029)
9.2.3 Asia PEGylated Drugs Market Share by Type (2018-2029)
9.3 Asia PEGylated Drugs Market Size by Application
9.3.1 Asia PEGylated Drugs Market Size by Application (2018-2024)
9.3.2 Asia PEGylated Drugs Market Size by Application (2024-2029)
9.3.3 Asia PEGylated Drugs Market Share by Application (2018-2029)
9.4 Asia PEGylated Drugs Market Size by Region
9.4.1 Asia PEGylated Drugs Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia PEGylated Drugs Market Size by Region (2018-2024)
9.4.3 Asia PEGylated Drugs Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America PEGylated Drugs Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Type
10.2.1 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America PEGylated Drugs Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Application
10.3.1 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America PEGylated Drugs Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country
10.4.1 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Details
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PEGylated Drugs Introduction
11.1.4 AstraZeneca Revenue in PEGylated Drugs Business (2018-2024)
11.1.5 AstraZeneca Recent Developments
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Details
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare PEGylated Drugs Introduction
11.2.4 Bayer Healthcare Revenue in PEGylated Drugs Business (2018-2024)
11.2.5 Bayer Healthcare Recent Developments
11.3 Biogen
11.3.1 Biogen Company Details
11.3.2 Biogen Business Overview
11.3.3 Biogen PEGylated Drugs Introduction
11.3.4 Biogen Revenue in PEGylated Drugs Business (2018-2024)
11.3.5 Biogen Recent Developments
11.4 BioMarin Pharmaceutical Inc
11.4.1 BioMarin Pharmaceutical Inc Company Details
11.4.2 BioMarin Pharmaceutical Inc Business Overview
11.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Introduction
11.4.4 BioMarin Pharmaceutical Inc Revenue in PEGylated Drugs Business (2018-2024)
11.4.5 BioMarin Pharmaceutical Inc Recent Developments
11.5 Coherus BioSciences
11.5.1 Coherus BioSciences Company Details
11.5.2 Coherus BioSciences Business Overview
11.5.3 Coherus BioSciences PEGylated Drugs Introduction
11.5.4 Coherus BioSciences Revenue in PEGylated Drugs Business (2018-2024)
11.5.5 Coherus BioSciences Recent Developments
11.6 Enzon
11.6.1 Enzon Company Details
11.6.2 Enzon Business Overview
11.6.3 Enzon PEGylated Drugs Introduction
11.6.4 Enzon Revenue in PEGylated Drugs Business (2018-2024)
11.6.5 Enzon Recent Developments
11.7 Horizon Therapeutics
11.7.1 Horizon Therapeutics Company Details
11.7.2 Horizon Therapeutics Business Overview
11.7.3 Horizon Therapeutics PEGylated Drugs Introduction
11.7.4 Horizon Therapeutics Revenue in PEGylated Drugs Business (2018-2024)
11.7.5 Horizon Therapeutics Recent Developments
11.8 Leadiant Biosciences, Inc.
11.8.1 Leadiant Biosciences, Inc. Company Details
11.8.2 Leadiant Biosciences, Inc. Business Overview
11.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Introduction
11.8.4 Leadiant Biosciences, Inc. Revenue in PEGylated Drugs Business (2018-2024)
11.8.5 Leadiant Biosciences, Inc. Recent Developments
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck PEGylated Drugs Introduction
11.9.4 Merck Revenue in PEGylated Drugs Business (2018-2024)
11.9.5 Merck Recent Developments
11.10 Mylan
11.10.1 Mylan Company Details
11.10.2 Mylan Business Overview
11.10.3 Mylan PEGylated Drugs Introduction
11.10.4 Mylan Revenue in PEGylated Drugs Business (2018-2024)
11.10.5 Mylan Recent Developments
11.11 Novo Nordisk
11.11.1 Novo Nordisk Company Details
11.11.2 Novo Nordisk Business Overview
11.11.3 Novo Nordisk PEGylated Drugs Introduction
11.11.4 Novo Nordisk Revenue in PEGylated Drugs Business (2018-2024)
11.11.5 Novo Nordisk Recent Developments
11.12 Pfizer
11.12.1 Pfizer Company Details
11.12.2 Pfizer Business Overview
11.12.3 Pfizer PEGylated Drugs Introduction
11.12.4 Pfizer Revenue in PEGylated Drugs Business (2018-2024)
11.12.5 Pfizer Recent Developments
11.13 Roche
11.13.1 Roche Company Details
11.13.2 Roche Business Overview
11.13.3 Roche PEGylated Drugs Introduction
11.13.4 Roche Revenue in PEGylated Drugs Business (2018-2024)
11.13.5 Roche Recent Developments
11.14 Sandoz
11.14.1 Sandoz Company Details
11.14.2 Sandoz Business Overview
11.14.3 Sandoz PEGylated Drugs Introduction
11.14.4 Sandoz Revenue in PEGylated Drugs Business (2018-2024)
11.14.5 Sandoz Recent Developments
11.15 Servier Pharmaceuticals LLC
11.15.1 Servier Pharmaceuticals LLC Company Details
11.15.2 Servier Pharmaceuticals LLC Business Overview
11.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Introduction
11.15.4 Servier Pharmaceuticals LLC Revenue in PEGylated Drugs Business (2018-2024)
11.15.5 Servier Pharmaceuticals LLC Recent Developments
11.16 Takeda Pharmaceutical Company Limited
11.16.1 Takeda Pharmaceutical Company Limited Company Details
11.16.2 Takeda Pharmaceutical Company Limited Business Overview
11.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Introduction
11.16.4 Takeda Pharmaceutical Company Limited Revenue in PEGylated Drugs Business (2018-2024)
11.16.5 Takeda Pharmaceutical Company Limited Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global PEGylated Drugs Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Macromolecular Drugs
Table 3. Key Players of Small Molecular Drugs
Table 4. Key Players of Nanoparticles
Table 5. Global PEGylated Drugs Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 6. Global PEGylated Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 7. Global PEGylated Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 8. Global PEGylated Drugs Market Share by Region (2018-2024)
Table 9. Global PEGylated Drugs Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 10. Global PEGylated Drugs Market Share by Region (2024-2029)
Table 11. PEGylated Drugs Market Trends
Table 12. PEGylated Drugs Market Drivers
Table 13. PEGylated Drugs Market Challenges
Table 14. PEGylated Drugs Market Restraints
Table 15. Global PEGylated Drugs Revenue by Players (2018-2024) & (US$ Million)
Table 16. Global PEGylated Drugs Revenue Share by Players (2018-2024)
Table 17. Global Top PEGylated Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2022)
Table 18. Global PEGylated Drugs Industry Ranking 2021 VS 2022 VS 2024
Table 19. Global 5 Largest Players Market Share by PEGylated Drugs Revenue (CR5 and HHI) & (2018-2024)
Table 20. Global Key Players of PEGylated Drugs, Headquarters and Area Served
Table 21. Global Key Players of PEGylated Drugs, Product and Application
Table 22. Global Key Players of PEGylated Drugs, Product and Application
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 25. Global PEGylated Drugs Revenue Market Share by Type (2018-2024)
Table 26. Global PEGylated Drugs Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 27. Global PEGylated Drugs Revenue Market Share by Type (2024-2029)
Table 28. Global PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 29. Global PEGylated Drugs Revenue Share by Application (2018-2024)
Table 30. Global PEGylated Drugs Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 31. Global PEGylated Drugs Revenue Share by Application (2024-2029)
Table 32. North America PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 33. North America PEGylated Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 34. North America PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 35. North America PEGylated Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 36. North America PEGylated Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 37. North America PEGylated Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 38. North America PEGylated Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 39. Europe PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 40. Europe PEGylated Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 41. Europe PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 42. Europe PEGylated Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 43. Europe PEGylated Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Europe PEGylated Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 45. Europe PEGylated Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 46. China PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 47. China PEGylated Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 48. China PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 49. China PEGylated Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 50. Asia PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 51. Asia PEGylated Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 52. Asia PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 53. Asia PEGylated Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 54. Asia PEGylated Drugs Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 55. Asia PEGylated Drugs Market Size by Region (2018-2024) & (US$ Million)
Table 56. Asia PEGylated Drugs Market Size by Region (2024-2029) & (US$ Million)
Table 57. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Type (2018-2024) & (US$ Million)
Table 58. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Type (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Application (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Application (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America PEGylated Drugs Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 62. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country (2018-2024) & (US$ Million)
Table 63. Middle East, Africa, and Latin America PEGylated Drugs Market Size by Country (2024-2029) & (US$ Million)
Table 64. AstraZeneca Company Details
Table 65. AstraZeneca Business Overview
Table 66. AstraZeneca PEGylated Drugs Product
Table 67. AstraZeneca Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 68. AstraZeneca Recent Developments
Table 69. Bayer Healthcare Company Details
Table 70. Bayer Healthcare Business Overview
Table 71. Bayer Healthcare PEGylated Drugs Product
Table 72. Bayer Healthcare Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 73. Bayer Healthcare Recent Developments
Table 74. Biogen Company Details
Table 75. Biogen Business Overview
Table 76. Biogen PEGylated Drugs Product
Table 77. Biogen Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 78. Biogen Recent Developments
Table 79. BioMarin Pharmaceutical Inc Company Details
Table 80. BioMarin Pharmaceutical Inc Business Overview
Table 81. BioMarin Pharmaceutical Inc PEGylated Drugs Product
Table 82. BioMarin Pharmaceutical Inc Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 83. BioMarin Pharmaceutical Inc Recent Developments
Table 84. Coherus BioSciences Company Details
Table 85. Coherus BioSciences Business Overview
Table 86. Coherus BioSciences PEGylated Drugs Product
Table 87. Coherus BioSciences Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 88. Coherus BioSciences Recent Developments
Table 89. Enzon Company Details
Table 90. Enzon Business Overview
Table 91. Enzon PEGylated Drugs Product
Table 92. Enzon Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 93. Enzon Recent Developments
Table 94. Horizon Therapeutics Company Details
Table 95. Horizon Therapeutics Business Overview
Table 96. Horizon Therapeutics PEGylated Drugs Product
Table 97. Horizon Therapeutics Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 98. Horizon Therapeutics Recent Developments
Table 99. Leadiant Biosciences, Inc. Company Details
Table 100. Leadiant Biosciences, Inc. Business Overview
Table 101. Leadiant Biosciences, Inc. PEGylated Drugs Product
Table 102. Leadiant Biosciences, Inc. Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 103. Leadiant Biosciences, Inc. Recent Developments
Table 104. Merck Company Details
Table 105. Merck Business Overview
Table 106. Merck PEGylated Drugs Product
Table 107. Merck Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 108. Merck Recent Developments
Table 109. Mylan Company Details
Table 110. Mylan Business Overview
Table 111. Mylan PEGylated Drugs Product
Table 112. Mylan Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 113. Mylan Recent Developments
Table 114. Novo Nordisk Company Details
Table 115. Novo Nordisk Business Overview
Table 116. Novo Nordisk PEGylated Drugs Product
Table 117. Novo Nordisk Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 118. Novo Nordisk Recent Developments
Table 119. Pfizer Company Details
Table 120. Pfizer Business Overview
Table 121. Pfizer PEGylated Drugs Product
Table 122. Pfizer Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 123. Pfizer Recent Developments
Table 124. Roche Company Details
Table 125. Roche Business Overview
Table 126. Roche PEGylated Drugs Product
Table 127. Roche Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 128. Roche Recent Developments
Table 129. Sandoz Company Details
Table 130. Sandoz Business Overview
Table 131. Sandoz PEGylated Drugs Product
Table 132. Sandoz Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 133. Sandoz Recent Developments
Table 134. Servier Pharmaceuticals LLC Company Details
Table 135. Servier Pharmaceuticals LLC Business Overview
Table 136. Servier Pharmaceuticals LLC PEGylated Drugs Product
Table 137. Servier Pharmaceuticals LLC Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 138. Servier Pharmaceuticals LLC Recent Developments
Table 139. Takeda Pharmaceutical Company Limited Company Details
Table 140. Takeda Pharmaceutical Company Limited Business Overview
Table 141. Takeda Pharmaceutical Company Limited PEGylated Drugs Product
Table 142. Takeda Pharmaceutical Company Limited Revenue in PEGylated Drugs Business (2018-2024) & (US$ Million)
Table 143. Takeda Pharmaceutical Company Limited Recent Developments
Table 144. Research Programs/Design for This Report
Table 145. Key Data Information from Secondary Sources
Table 146. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PEGylated Drugs Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global PEGylated Drugs Market Share by Type: 2022 VS 2029
Figure 3. Macromolecular Drugs Features
Figure 4. Small Molecular Drugs Features
Figure 5. Nanoparticles Features
Figure 6. Global PEGylated Drugs Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 7. Global PEGylated Drugs Market Share by Application: 2022 VS 2029
Figure 8. Cancer Case Studies
Figure 9. Hepatitis C Case Studies
Figure 10. Leukemia Case Studies
Figure 11. Severe Combined Immunodeficiency Disease Case Studies
Figure 12. Rheumatoid Arthritis Case Studies
Figure 13. Crohn Disease Case Studies
Figure 14. Others Case Studies
Figure 15. PEGylated Drugs Report Years Considered
Figure 16. Global PEGylated Drugs Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 17. Global PEGylated Drugs Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global PEGylated Drugs Market Share by Region: 2022 VS 2029
Figure 19. Global PEGylated Drugs Market Share by Players in 2022
Figure 20. Global Top PEGylated Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PEGylated Drugs as of 2022)
Figure 21. The Top 10 and 5 Players Market Share by PEGylated Drugs Revenue in 2022
Figure 22. North America PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 23. North America PEGylated Drugs Market Share by Type (2018-2029)
Figure 24. North America PEGylated Drugs Market Share by Application (2018-2029)
Figure 25. North America PEGylated Drugs Market Share by Country (2018-2029)
Figure 26. United States PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 27. Canada PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. Europe PEGylated Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 29. Europe PEGylated Drugs Market Share by Type (2018-2029)
Figure 30. Europe PEGylated Drugs Market Share by Application (2018-2029)
Figure 31. Europe PEGylated Drugs Market Share by Country (2018-2029)
Figure 32. Germany PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. France PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. U.K. PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Italy PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Russia PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. Nordic Countries PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. China PEGylated Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 39. China PEGylated Drugs Market Share by Type (2018-2029)
Figure 40. China PEGylated Drugs Market Share by Application (2018-2029)
Figure 41. Asia PEGylated Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 42. Asia PEGylated Drugs Market Share by Type (2018-2029)
Figure 43. Asia PEGylated Drugs Market Share by Application (2018-2029)
Figure 44. Asia PEGylated Drugs Market Share by Region (2018-2029)
Figure 45. Japan PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. South Korea PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. China Taiwan PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Southeast Asia PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. India PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 50. Australia PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 51. Middle East, Africa, and Latin America PEGylated Drugs Market Size YoY (2018-2029) & (US$ Million)
Figure 52. Middle East, Africa, and Latin America PEGylated Drugs Market Share by Type (2018-2029)
Figure 53. Middle East, Africa, and Latin America PEGylated Drugs Market Share by Application (2018-2029)
Figure 54. Middle East, Africa, and Latin America PEGylated Drugs Market Share by Country (2018-2029)
Figure 55. Brazil PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Mexico PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Turkey PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. Saudi Arabia PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Israel PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 60. GCC Countries PEGylated Drugs Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 61. AstraZeneca Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 62. Bayer Healthcare Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 63. Biogen Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 64. BioMarin Pharmaceutical Inc Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 65. Coherus BioSciences Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 66. Enzon Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 67. Horizon Therapeutics Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 68. Leadiant Biosciences, Inc. Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 69. Merck Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 70. Mylan Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 71. Novo Nordisk Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 72. Pfizer Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 73. Roche Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 74. Sandoz Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 75. Servier Pharmaceuticals LLC Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 76. Takeda Pharmaceutical Company Limited Revenue Growth Rate in PEGylated Drugs Business (2018-2024)
Figure 77. Bottom-up and Top-down Approaches for This Report
Figure 78. Data Triangulation
Figure 79. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries